主要文書

すべての文書を表示

1672803

USP

trans-白金(II)ジアンミンジクロリド

Name: <I>trans</I>-白金(II)ジアンミンジクロリド
Brand: USP

United States Pharmacopeia (USP) Reference Standard

別名:

trans-ジアンミンジクロロ白金(II), trans-ジクロロジアンミン白金(II)

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

化学式:

Pt(NH₃)₂Cl₂

CAS番号:

14913-33-8

分子量:

300.05

NACRES:

NA.24

PubChem Substance ID:

329751363

UNSPSC Code:

41116107

MDL number:

MFCD00011623

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

特性

grade

pharmaceutical primary standard

API family

cisplatin

manufacturer/tradename

USP

mp

340 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

詳細

General description

この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under trans-白金(II)ジアンミンジクロリド

pictograms

GHS08,GHS05

signalword

Danger

hcodes

H317,H318,H334

pcodes

P280 - P302 + P352 - P305 + P351 + P338 + P310

Hazard Classifications

Eye Dam. 1 - Resp. Sens. 1 - Skin Sens. 1

保管分類

13 - Non Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせくださいカスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

James Chih-Hsin Yang et al.

The Lancet. Oncology, 16(2), 141-151 (2015-01-16)

We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

Xi-Chun Hu et al.

The Lancet. Oncology, 16(4), 436-446 (2015-03-22)

Platinum chemotherapy has a role in the treatment of metastatic triple-negative breast cancer but its full potential has probably not yet been reached. We assessed whether a cisplatin plus gemcitabine regimen was non-inferior to or superior to paclitaxel plus gemcitabine

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.

Koichi Azuma et al.

Oncotarget, 5(15), 5908-5919 (2014-08-15)

Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to